Literature DB >> 33305608

Prognostic implications of depression and inflammation in patients with metastatic lung cancer.

Daniel C McFarland1, Rebecca M Saracino1, Andrew H Miller2, William Breitbart1, Barry Rosenfeld3, Christian Nelson1.   

Abstract

Background: Lung cancer-related inflammation is associated with depression. Both elevated inflammation and depression are associated with worse survival. However, outcomes of patients with concomitant depression and elevated inflammation are not known. Materials & methods: Patients with metastatic lung cancer (n = 123) were evaluated for depression and inflammation. Kaplan-Meier plots and Cox proportional hazard models provided survival estimations.
Results: Estimated survival was 515 days for the cohort and 323 days for patients with depression (hazard ratio: 1.12; 95% CI: 1.05-1.179), 356 days for patients with elevated inflammation (hazard ratio: 2.85, 95% CI: 1.856-4.388), and 307 days with both (χ2 = 12.546; p < 0.001]).
Conclusion: Depression and inflammation are independently associated with inferior survival. Survival worsened by inflammation is mediated by depression-a treatable risk factor.

Entities:  

Keywords:  C-reactive protein; depression; depressive symptoms; immune function; inflammation; lung cancer; prognosis; survival

Mesh:

Year:  2020        PMID: 33305608      PMCID: PMC7857340          DOI: 10.2217/fon-2020-0632

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  61 in total

1.  Inflammatory profiles of severe treatment-resistant depression.

Authors:  Rebecca Strawbridge; John Hodsoll; Timothy R Powell; Matthew Hotopf; Stephani L Hatch; Gerome Breen; Anthony J Cleare
Journal:  J Affect Disord       Date:  2018-12-17       Impact factor: 4.839

2.  Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab.

Authors:  L Traki; S Rostom; L Tahiri; R Bahiri; T Harzy; R Abouqal; N Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

3.  Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy Greer; Bruce Grannemann; Abigail Soyombo; Taryn L Mayes; A John Rush; Madhukar H Trivedi
Journal:  Psychoneuroendocrinology       Date:  2017-01-24       Impact factor: 4.905

4.  Why doesn't depression treatment improve cancer survival?

Authors:  Alex J Mitchell
Journal:  Lancet Psychiatry       Date:  2018-03-12       Impact factor: 27.083

Review 5.  An Act of Balance Between Adaptive and Maladaptive Immunity in Depression: a Role for T Lymphocytes.

Authors:  Catherine Toben; Bernhard T Baune
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-02       Impact factor: 4.147

Review 6.  Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets.

Authors:  Błażej Misiak; Jan Aleksander Beszłej; Kamila Kotowicz; Monika Szewczuk-Bogusławska; Jerzy Samochowiec; Jolanta Kucharska-Mazur; Dorota Frydecka
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-04-19       Impact factor: 5.067

7.  A new automated turbidimetric immunoassay for the measurement of canine C-reactive protein.

Authors:  Matilde Piñeiro; Raquel Pato; Lourdes Soler; Raquel Peña; Natalia García; Carlos Torrente; Yolanda Saco; Fermín Lampreave; Anna Bassols; Francesca Canalias
Journal:  Vet Clin Pathol       Date:  2018-01-29       Impact factor: 1.180

8.  Sputum interleukin-6, tumor necrosis factor-α and Salivary cortisol as new biomarkers of depression in lung cancer patients.

Authors:  Yi-jie Du; Hong-ying Zhang; Bei Li; Xiao Wu; Yu-bao Lv; Hua-liang Jin; Yu-xue Cao; Jing Sun; Qing-li Luo; Wei-yi Gong; Bao-jun Liu; Jin-feng Wu; Shen-xun Shi; Jing-cheng Dong
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-08-19       Impact factor: 5.067

9.  Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer.

Authors:  Oscar Arrieta; Laura P Angulo; Carolina Núñez-Valencia; Yuzmiren Dorantes-Gallareta; Eleazar O Macedo; Dulce Martínez-López; Salvador Alvarado; José-Francisco Corona-Cruz; Luis F Oñate-Ocaña
Journal:  Ann Surg Oncol       Date:  2012-12-22       Impact factor: 5.344

10.  Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.

Authors:  Lorenzo Cohen; Steven W Cole; Anil K Sood; Sarah Prinsloo; Clemens Kirschbaum; Jesusa M G Arevalo; Nicholas B Jennings; Shellie Scott; Luis Vence; Qi Wei; Diane Kentor; Laszlo Radvanyi; Nizar Tannir; Eric Jonasch; Pheroze Tamboli; Louis Pisters
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

View more
  4 in total

1.  Depressive symptoms and shorter survival in lung cancer: the role of leukocyte telomere length.

Authors:  Chelsea J Siwik; Elizabeth Cash; Sandra E Sephton
Journal:  Psychol Health       Date:  2022-03-03

2.  Cancer-related inflammation and depressive symptoms: Systematic review and meta-analysis.

Authors:  Daniel C McFarland; Meredith Doherty; Thomas M Atkinson; Robin O'Hanlon; William Breitbart; Christian J Nelson; Andrew H Miller
Journal:  Cancer       Date:  2022-04-13       Impact factor: 6.921

3.  Longitudinal Association of Universal Screening and Treatment for Major Depressive Disorder with Survival in Cancer Patients.

Authors:  Yung-Chieh Yen; Chin-Yu Huang; Hsue-Wei Chan; You-Yu Wang; Te-Chang Changchien; Deng-Wu Wang; Po-Chun Lin; Ting-Ting Chang; Yu-Wen Chiu
Journal:  J Pers Med       Date:  2022-07-26

Review 4.  Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine.

Authors:  Oscar Fraile-Martinez; Miguel A Alvarez-Mon; Cielo Garcia-Montero; Leonel Pekarek; Luis G Guijarro; Guillermo Lahera; Miguel A Saez; Jorge Monserrat; Domitila Motogo; Javier Quintero; Melchor Alvarez-Mon; Miguel A Ortega
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.